Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381257 | 1.00 | LMNA (0.55) | LMNAHTTHRH3GPR119KDM4E | |
| SCHEMBL20152892 | 0.88 | HRH3 (0.53) | LMNAHRH3GPR119KDM4EL3MBTL1 | |
| SCHEMBL19998593 | 0.87 | LMNA (0.65) | LMNAHRH3GPR119KDM4EL3MBTL1 | |
| SCHEMBL24663638 | 0.85 | HRH3 (0.57) | LMNAHRH3GPR119KDM4EL3MBTL1 | |
| SCHEMBL10174357 | 0.84 | KDM4E (0.61) | LMNAHRH3GPR119KDM4EL3MBTL1 | |
| SCHEMBL1977631 | 0.83 | LMNA (0.56) | LMNAHTTKDM4EHSD17B10USP2 | |
| SCHEMBL327068 | 0.82 | HRH3 (0.55) | LMNAHTTHRH3KDM4EHSD17B10 | |
| SCHEMBL10174320 | 0.82 | USP30 (0.57) | HRH3L3MBTL1POLB | |
| SCHEMBL15205885 | 0.82 | LMNA (0.55) | LMNAHTTKDM4EHSD17B10USP2 | |
| SCHEMBL14605216 | 0.82 | LMNA (0.55) | LMNAHTTHRH3KDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-4553068-A1 | PYRIMIDINE DERIVATIVES | ASKA Pharmaceutical Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024010015-A1 | PYRIMIDINE DERIVATIVES | あすか製薬株式会社 | 2024-01-11 | — | — | WO | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-3298002-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | LMNA 4722/4885HTT 590/4885HRH3 201/4885 |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | LMNA 3914/4885HTT 4400/4885HRH3 735/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | LMNA 4043/4885HTT 4415/4885HRH3 649/4885 |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | LMNA 4701/4885HTT 420/4885HRH3 235/4885 |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | PTGES, PTGS1, PTGIS | LMNA 4184/4885HTT 4866/4885HRH3 1518/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | LMNA 4043/4885HTT 4415/4885HRH3 649/4885 |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | LMNA 4043/4885HTT 4415/4885HRH3 649/4885 |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | LMNA 4046/4885HTT 3230/4885HRH3 292/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | LMNA 3914/4885HTT 4400/4885HRH3 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.